2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 249

Patients with Fibromyalgia May be Fearful of Developing Dementia Despite Lack of Concrete Evidence of Cognitive Decline
Abstract Number: 931

Patients with Seropositive Rheumatoid Arthritis Who Do Not Mount a CRP Response When They Have Synovitis Are Immunologically Distinct and Are Poorly Served By Current Management Strategies
Abstract Number: 1178

Patients’ and Healthcare Professionals’ Resource Preferences for a Knowledge Translation Toolkit for Hip and Knee Replacement Rehabilitation
Abstract Number: 2492

Pattern Shift and Influential Factors in Promoting Treat-to-Target (T2T) for Follow-up RA Patients with a Rheumatologist-Patient Interactive Smart System of Disease Management (SSDM): A Cohort Study from China
Abstract Number: 1619

Patterns and Outcomes on As Patients Disease Activity Using Smart System of Disease Management (SSDM): Analysis of T2T Pattern Shift and the Correlation between Disease Activity and Mental Health
Abstract Number: 267

Patterns of Access to Prescription Medications Among Lupus Cases and Controls in the Population-Based Michigan Lupus Epidemiology & Surveillance (MILES) Cohort
Abstract Number: 1891

Patterns of Biosimilar Use in the Rheumatology Informatics System for Effectiveness (RISE) Registry
Abstract Number: 619

Patterns of Change of a Second Biological Dmard in a Cohort of Patients with Rheumatoid Arthritis
Abstract Number: 1163

Patterns of Depressive Symptoms before and after Surgery for Hip, Knee and Lumbar Spine Osteoarthritis
Abstract Number: 1889

Patterns of Glucocorticoid Use and Provider-Level Variation in a Commercially Insured Incident Rheumatoid Arthritis Population
Abstract Number: 2613

Patterns of Medication Use in a Validated Cohort of Psoriatic Arthritis (PsA) Patients
Abstract Number: 866

Patterns of Monosodium Urate Deposition on Dual-Energy CT in Gout Patients on Urate-Lowering Therapy
Abstract Number: 319

Patterns of Muscle Oedema, Atrophy and Fatty Replacement in the Idiopathic Inflammatory Myopathies: A Single-Centre Retrospective Review of Magnetic Resonance Imaging Data
Abstract Number: 1154

Patterns of Opioid Use and Patient Characteristics before Total Hip and Knee Replacement
Abstract Number: 150

PD-1 Signaling Interferes with OX40L to Alter the Suppressive Function and Proliferation of CD4+ Regulatory T Cells in Lupus Mice

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].